| MFN1, MFN2, and OPA1 are mostly AD / neurodegeneration-relevant pathway targets:
In AD, the general pattern is: fusion proteins MFN1, MFN2, and OPA1 tend to be reduced or functionally impaired, while fission signaling such as DRP1/FIS1 is often increased, contributing to fragmented mitochondria, synaptic injury, oxidative stress, and impaired bioenergetics
MFN1, MFN2, and OPA1 are mitochondrial fusion regulators.
MFN1 and MFN2 mediate outer mitochondrial membrane fusion, while OPA1
mediates inner mitochondrial membrane fusion and helps maintain cristae
structure. In Alzheimer’s disease and related neurodegenerative models,
mitochondrial dynamics are commonly shifted toward excessive fragmentation,
with reduced or impaired fusion signaling and increased fission stress.
Restoring MFN2/OPA1/MFN1 activity may help preserve mitochondrial network
integrity, oxidative phosphorylation, neuronal transport, calcium handling,
and synaptic resilience.
| Target / Pathway |
Primary Disease Relevance |
Normal Function |
Observed / Suspected Change in AD |
Therapeutic Direction |
Database Interpretation |
Evidence Strength |
Notes for Product Screening |
| MFN1 |
Mostly AD / neurodegeneration; secondary cancer relevance |
Outer mitochondrial membrane fusion protein. Works with MFN2 to tether
and fuse adjacent mitochondria, helping maintain mitochondrial network
integrity and mitochondrial DNA/protein complementation.
|
Generally reported as reduced or functionally impaired in AD-related
mitochondrial dynamics imbalance, contributing to mitochondrial
fragmentation and reduced neuronal bioenergetic resilience.
|
Support / restore mitochondrial fusion where excessive fission and
mitochondrial fragmentation are present.
|
Pathway target rather than product. Useful as part of a broader
“mitochondrial fusion support” or “anti-fragmentation” pathway entry.
|
Moderate |
Track products that increase MFN1 expression, improve mitochondrial
network morphology, reduce DRP1-driven fragmentation, or restore
fusion/fission balance.
|
| MFN2 |
Strong AD / neurodegeneration relevance; also cancer and metabolic relevance |
Outer mitochondrial membrane fusion protein. Also involved in
mitochondria-ER contact regulation, calcium handling, mitophagy-related
quality control, mitochondrial trafficking, and cellular stress adaptation.
|
MFN2 dysfunction or downregulation is associated with impaired
mitochondrial fusion, abnormal mitochondria-ER communication,
calcium stress, oxidative stress, synaptic vulnerability, and possibly
amyloid/tau-associated mitochondrial injury.
|
Usually upmodulation / restoration is desirable in AD models where
mitochondrial fragmentation, poor transport, or excessive fission is present.
|
High-priority AD target. Best entered as a mitochondrial dynamics,
fusion, ER-mitochondria contact, and mitophagy-quality-control target.
|
Moderate-Strong |
Track products that increase MFN2, improve mitochondrial elongation,
reduce Aβ/tau-induced mitochondrial fragmentation, improve calcium
homeostasis, or restore mitochondrial transport in neurons.
|
| OPA1 |
Strong AD / neurodegeneration relevance; also apoptosis and cancer relevance |
Inner mitochondrial membrane fusion protein. Maintains cristae structure,
supports oxidative phosphorylation, preserves mitochondrial membrane
organization, and helps regulate cytochrome-c release during apoptosis.
|
OPA1 loss or cleavage can reduce inner membrane fusion, destabilize
cristae, impair oxidative phosphorylation, increase mitochondrial
fragmentation, and sensitize neurons to synaptic and metabolic stress.
|
Support / stabilize OPA1 activity, especially long-form fusion-active OPA1,
where mitochondrial stress causes excessive OPA1 cleavage and fragmentation.
|
High-priority AD target. Best entered under mitochondrial fusion,
cristae integrity, oxidative phosphorylation, and apoptosis-resistance
pathways.
|
Moderate-Strong |
Track products that preserve OPA1, reduce pathological OPA1 cleavage,
improve cristae integrity, improve ATP production, or reduce
mitochondrial apoptosis signaling.
|
|